See this page online at: http://www.bioscienceworld.ca/2008Issue3


  • Make this your homepage
  • Print this Page


Magazine

Sign up for your free subscription and keep up-to-date.


Upcoming Events


Newsletters

Stay updated on the latest news and technologies with Bioscienceworld's newsletters.
Five to choose from.


Email Address

March 2008

Volume 11, Issue 3

New blueprint for green buildings focuses on eco-efficiency
By Rick Whittaker

When Canadians think about energy consumption and greenhouse gas emissions (GHGs), many of us link these issues to large emitters in the industry and resource sectors. But there are many, less obvious sources of GHGs that have a definite impact on our environment - and as you read this article, chances are you're sitting in one right now.

Proteomics: An Expensive Science
By Shawn Lawrence

Proteomics is the study of the structure and
function of protein, just as every living thing has a complete set of DNA known as its genome, people all carry a full complement of proteins known as the proteome. In Canada, the benefits from proteomic research have been felt in such areas as healthcare, agriculture, forestry and the environment. The understanding gained from it has lead to new insights into how different diseases might be prevented, diagnosed and treated.

Cultivating Canada's Science and Technology
By Karen Harrison

Government leadership and investment in science and technology has played a significant role in stimulating innovation, knowledge and wealth creation across Canada. As the federal government begins to implement the strategic directions of Mobilizing Science and Technology to Canada's Advantage, released in May 2007, Pierre Coulombe, president of the National Research Council of Canada (NRC), spoke with Biotechnology Focus about the plan and the council.

Pharma's New Worldview: Transforming R&D Through Emerging Markets
By Heather Fraser

To date, research and development (R&D) in the pharmaceutical industry has been dominated by a developed markets perspective. But as emerging markets change pharmaceutical companies' worldview, its time for drug makers tofundamentally rethink how R&D is done.